|
|
Vaccine Detail
|
Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007218
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: CD80
- CD80
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: (Frankowski et al., 2004)
- Description: An allogeneic whole cell vaccine, derived from irradiated allogenic tumor cells manipulated to express human B7.1 (CD80 antigen) and human leukocyte antigen (HLA) A1, with potential antitumor activity. Vaccination with allogeneic B7.1/HLA-A1 transfected tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor cell proliferation. (NCIT_C70985).
This cancer vaccine has been used in NSCLC trials. (Raez et al., 2003)
|
| Host Response |
|
|
| References |
Frankowski et al., 2004: Frankowski DJ, Raez J, Manners I, Winnik MA, Khan SA, Spontak RJ. Formation of dispersed nanostructures from poly(ferrocenyldimethylsilane-b-dimethylsiloxane) nanotubes upon exposure to supercritical carbon dioxide. Langmuir : the ACS journal of surfaces and colloids. 2004; 20(21); 9304-9314. [PubMed: 15461522].
NCIT_C70985: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C70985]
Raez et al., 2003: Raez LE, Cassileth PA, Schlesselman JJ, Padmanabhan S, Fisher EZ, Baldie PA, Sridhar K, Podack ER. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer gene therapy. 2003; 10(11); 850-858. [PubMed: 14605671].
|
|
